Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: Médecins Sans Frontières experience in the Democratic Republic of the Congo

Clinical Infectious Diseases

Volumn 56, Issue 2, 2013, Pages 195-203

  Alirol, Emilie ^a,b   Schrumpf, David ^a,b   Amici Heradi, Josué ^b   Riedel, Andrea ^b   De Patoul, Catherine ^b   Quere, Michel ^b   Chappuis, François ^a,b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b MÉDECINS SANS FRONTIÈRES   (Switzerland)

Author keywords

Democratic Republic of Congo; human african trypanosomiasis; NECT; pharmacovigilance; safety

Indexed keywords

EFLORNITHINE; MELARSOPROL; NIFURTIMOX; PENTAMIDINE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AFRICAN TRYPANOSOMIASIS; ANOREXIA; ARTICLE; CEREBROSPINAL FLUID; CHILD; CONGO; CONVULSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MOOD CHANGE; MORTALITY; MUSCULOSKELETAL PAIN; NAUSEA; PRESCHOOL CHILD; PRIORITY JOURNAL; PRURITUS; PSYCHOSIS; RELAPSE; SCHOOL CHILD; SIDE EFFECT; STOMACH PAIN; TREMOR; TRYPANOSOMA; TRYPANOSOMA GAMBIENSE; VOMITING;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DEMOCRATIC REPUBLIC OF THE CONGO; DRUG THERAPY, COMBINATION; EFLORNITHINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NIFURTIMOX; RISK FACTORS; TREATMENT OUTCOME; TRYPANOSOMA BRUCEI GAMBIENSE; TRYPANOSOMIASIS, AFRICAN; YOUNG ADULT;

EID: 84871778164     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis886     Document Type: Article

References (39)

1. Brun R, Blum J, Chappuis F, Burri C. Human African trypanosomia-sis. Lancet 2010; 375:148-59.
2. Fevre EM, Wissmann BV, Welburn SC, Lutumba P. The burden of human African trypanosomiasis. PLoS Negl Trop Dis 2008; 2:e333.
3. Human African trypanosomiasis (sleeping sickness): epidemiological update. Wkly Epidemiol Rec 2006; 81:71-80.
4. Chappuis F, Lima MA, Flevaud L, Ritmeijer K. Human African try-panosomiasis in areas without surveillance. Emerg Infect Dis 2010; 16:354-6.
5. Tong J, Valverde O, Mahoudeau C, Yun O, Chappuis F. Challenges of controlling sleeping sickness in areas of violent conflict: experience in the Democratic Republic of Congo. Confl Health 2011; 5:7.
6. Barrett MP, Burchmore RJ, Stich A, et al. The trypanosomiases. Lancet 2003; 362:1469-80. (Pubitemid 37352887)
7. Blum J, Schmid C, Burri C. Clinical aspects of 2541 patients with second stage human African trypanosomiasis. Acta Trop 2006; 97:55-64. (Pubitemid 41758517)
8. Barrett MP, Boykin DW, Brun R, Tidwell RR. Human African try-panosomiasis: pharmacological re-engagement with a neglected disease. Br J Pharmacol 2007; 152:1155-71. (Pubitemid 350242432)
9. Friedheim EA. Mel B in the treatment of human trypanosomiasis. Am J Trop Med Hyg 1949; 29:173-80.
10. Blum J, Nkunku S, Burri C. Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis. Trop Med Int Health 2001; 6:390-400. (Pubitemid 32510076)
11. Pepin J, Milord F, Khonde AN, et al. Risk factors for encephalopathy and mortality during melarsoprol treatment of Trypanosoma brucei gambiense sleeping sickness. Trans R Soc Trop Med Hyg 1995; 89:92-7.
12. Burri C, Keiser J. Pharmacokinetic investigations in patients from northern Angola refractory to melarsoprol treatment. Trop Med Int Health 2001; 6:412-20. (Pubitemid 32510079)
13. Legros D, Evans S, Maiso F, Enyaru JC, Mbulamberi D. Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gam-biense trypanosomiasis in Uganda. Trans R Soc Trop Med Hyg 1999; 93:439-42. (Pubitemid 29405880)
14. Robays J, Nyamowala G, Sese C, et al. High failure rates of melarso-prol for sleeping sickness, Democratic Republic of Congo. Emerg Infect Dis 2008; 14:966-7. (Pubitemid 351838613)
15. Schechter PJ, Sjoerdsma A. Difiuoromethylornithine in the treatment of African trypanosomiasis. Parasitol Today 1986; 2:223-4.
16. Priotto G, Pinoges L, Fursa IB, et al. Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study. BMJ 2008; 336:705-8. (Pubitemid 351481213)
17. Chappuis F, Udayraj N, Stietenroth K, Meussen A, Bovier PA. Eflorni-thine is safer than melarsoprol for the treatment of second-stage Try-panosoma brucei gambiense human African trypanosomiasis. Clin Infect Dis 2005; 41:748-51. (Pubitemid 41170365)
18. Balasegaram M, Harris S, Checchi F, et al. Melarsoprol versus eflorni-thine for treating late-stage Gambian trypanosomiasis in the Republic of the Congo. Bull World Health Organ 2006; 84:783-91. (Pubitemid 44610113)
19. Balasegaram M, Young H, Chappuis F, et al. Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Medecins Sans Frontieres programmes. Trans R Soc Trop Med Hyg 2009; 103:280-90.
20. Janssens PG, De Muynck A. Clinical trials with "nifurtimox" in African trypanosomiasis. Ann Soc Belg Med Trop 1977; 57:475-80. (Pubitemid 8234606)
21. Moens F, De Wilde M, Ngato K. Clinical trial of nifurtimox in human African trypanosomiasis. Ann Soc Belg Med Trop 1984; 64:37-43. (Pubitemid 14143746)
22. Pepin J, Milord F, Mpia B, et al. An open clinical trial of nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness in central Zaire. Trans R Soc Trop Med Hyg 1989; 83:514-7. (Pubitemid 19212073)
23. Checchi F, Piola P, Ayikoru H, et al. Nifurtimox plus eflornithine for late-stage sleeping sickness in Uganda: a case series. PLoS Negl Trop Dis 2007; 1:e64.
24. Priotto G, Fogg C, Balasegaram M, et al. Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda. PLoS Clin Trials 2006; 1:e39.
25. Priotto G, Kasparian S, Mutombo W, et al. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet 2009; 374:56-64.
26. World Health Organization. WHO includes combination of eflornithine and nifurtimox in its Essential List of Medicines for the treatment of human African trypanosomiasis, 2009. Available at: http://www.who.int/neglected-diseases/ disease-management/drug-combination/en/. Accessed 31 August 2012.
27. Valverde Mordt O, Schmid C, Kande C, et al. A multicenter, open label, phase III study of therapeutic use of the co-administration of nifurtimox and eflornithine (NECT) for human African trypanosomiasis (NECT FIELD): safety profile in children during initial hospi-talization. 7th European Congress on Tropical Medicine and International Health, Barcelona, Spain, 3-6 October 2011.
28. Magnus E, Vervoort T, Van Meirvenne N. A card-agglutination test with stained trypanosomes (C.A.T.T.) for the serological diagnosis of T. B. gambiense trypanosomiasis. Ann Soc Belg Med Trop 1978; 58:169-76. (Pubitemid 9068603)
29. Woo PT. The haematocrit centrifuge technique for the diagnosis of African trypanosomiasis. Acta Trop 1970; 27:384-6.
30. Lumsden WH, Kimber CD, Evans DA, Doig SJ. Trypanosoma brucei: miniature anion-exchange centrifugation technique for detection of low parasitaemias: adaptation for field use. Trans R Soc Trop Med Hyg 1979; 73:312-7. (Pubitemid 9215398)
31. Schopper D, Upshur R, Matthys F, et al. Research ethics review in humanitarian contexts: the experience of the independent ethics review board of Medecins Sans Frontieres. PLoS Med 2009; 6: e1000115.
32. Karnofsky D, Burchenal J. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, ed. Evaluation of chemotherapeu-tic agents. New York: Columbia University Press, 1949:196.
33. Altcheh J, Biancardi M, Lapena A, Ballering G, Freilij H. Congenital Chagas disease: experience in the Hospital de Ninos, Ricardo Gutierrez, Buenos Aires, Argentina. Rev Soc Bras Med Trop 2005; 38(suppl 2):41-5.
34. Castro JA, de Mecca MM, Bartel LC. Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis). Hum Exp Toxicol 2006; 25:471-9. (Pubitemid 44384589)
35. Saulnier Sholler GL, Bergendahl GM, Brard L, et al. A phase 1 study of nifurtimox in patients with relapsed/refractory neuroblastoma. J Pediatr Hematol Oncol 2011; 33:25-30.
36. Jackson Y, Alirol E, Getaz L, et al. Tolerance and safety of nifurtimox in patients with chronic Chagas disease. Clin Infect Dis 2010; 51: e69-75.
37. Yun O, Priotto G, Tong J, Flevaud L, Chappuis F. NECT is next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness. PLoS Negl Trop Dis 2010; 4:e720.
38. Simarro PP, Franco J, Diarra A, Postigo JA, Jannin J. Update on field use of the available drugs for the chemotherapy of human African trypanosomiasis. Parasitology 2012; 139:842-6.
39. Kaiser M, Bray MA, Cal M, et al. Antitrypanosomal activity of fexini-dazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness. Antimicrob Agents Chemother 2011; 55:5602-8.